Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/the-time-has-come-for-targeted-therapies-for-aml-lights-and-shadows-NN1VluX0X1
References (115)
-
Samah Nassereddine, Coen Lap, Faysal Haroun, I. Tabbara (2017)
The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemiaAnnals of Hematology, 96
-
C. Lehmann, T. Friess, Fabian Birzele, A. Kiialainen, M. Dangl (2016)
Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia modelsJournal of Hematology & Oncology, 9
-
A. Sadarangani, Gabriel Pineda, Kathleen Lennon, Hye-Jung Chun, Alice Shih, Annelie Schairer, A. Court, D. Goff, S. Prashad, I. Geron, Russell Wall, J. McPherson, Richard Moore, Minya Pu, L. Bao, A. Jackson-Fisher, M. Munchhof, T. Vanarsdale, T. Reya, S. Morris, M. Minden, Karen Messer, H. Mikkola, M. Marra, T. Hudson, C. Jamieson (2015)
GLI2 inhibition abrogates human leukemia stem cell dormancyJournal of Translational Medicine, 13
-
R. Assi, H. Kantarjian, N. Daver, G. Garcia-Manero, C. Benton, P. Thompson, G. Borthakur, T. Kadia, Y. Alvarado, E. Jabbour, M. Konopleva, Koichi Takahashi, S. Kornblau, C. Dinardo, Z. Estrov, W. Flores, Sreyashi Basu, J. Allison, P. Sharma, S. Pierce, Allison Pike, J. Cortes, F. Ravandi (2018)
Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)Blood
-
R. Stone (2018)
What FLT3 inhibitor holds the greatest promise?Best practice & research. Clinical haematology, 31 4
-
A. Roberts, M. Davids, J. Pagel, B. Kahl, S. Puvvada, J. Gerecitano, T. Kipps, M. Anderson, Jennifer Brown, Lori Gressick, S. Wong, M. Dunbar, Ming Zhu, Monali Desai, E. Cerri, Sari Enschede, R. Humerickhouse, W. Wierda, J. Seymour (2016)
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.The New England journal of medicine, 374 4
-
E. Stein, C. Dinardo, D. Pollyea, A. Fathi, G. Roboz, J. Altman, R. Stone, D. DeAngelo, R. Levine, I. Flinn, H. Kantarjian, R. Collins, M. Patel, A. Frankel, A. Stein, M. Sekeres, R. Swords, B. Medeiros, C. Willekens, P. Vyas, A. Tosolini, Qiang Xu, R. Knight, K. Yen, S. Agresta, S. Botton, M. Tallman (2017)
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.Blood, 130 6
-
A. Perl, G. Martinelli, J. Cortes, A. Neubauer, E. Berman, S. Paolini, P. Montesinos, M. Baer, R. Larson, C. Ustun, F. Fabbiano, H. Erba, A. Stasi, R. Stuart, R. Olin, M. Kasner, F. Ciceri, W. Chou, N. Podoltsev, C. Récher, Hisayuki Yokoyama, N. Hosono, S. Yoon, Je-Hwan Lee, T. Pardee, A. Fathi, Chaofeng Liu, N. Hasabou, Xuan Liu, E. Bahceci, M. Levis (2019)
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.The New England journal of medicine, 381 18
-
J. Lamba, Lata Chauhan, Miyoung Shin, M. Loken, J. Pollard, Yi-Cheng Wang, R. Ries, R. Aplenc, B. Hirsch, S. Raimondi, R. Walter, I. Bernstein, A. Gamis, T. Alonzo, S. Meshinchi (2017)
CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 23
-
M. Figueroa, O. Abdel-Wahab, Chao Lu, P. Ward, Jay Patel, A. Shih, Yushan Li, N. Bhagwat, A. Vasanthakumar, H. Fernandez, M. Tallman, Zhuoxin Sun, K. Wolniak, J. Peeters, Wei Liu, S. Choe, V. Fantin, E. Paietta, B. Löwenberg, J. Licht, L. Godley, R. Delwel, P. Valk, C. Thompson, R. Levine, A. Melnick (2010)
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.Cancer cell, 18 6
-
R. Hotchkiss, A. Strasser, J. McDunn, P. Swanson (2009)
Cell death.The New England journal of medicine, 361 16
-
T. Lin, W. Matsui (2012)
Hedgehog pathway as a drug target: Smoothened inhibitors in developmentOncoTargets and therapy, 5
-
A. Intlekofer, A. Shih, Bo Wang, Abbas Nazir, Ariën Rustenburg, Steven Albanese, Minal Patel, Christopher Famulare, Fabian Correa, N. Takemoto, Vidushi Durani, Hui Liu, Justin Taylor, N. Farnoud, E. Papaemmanuil, J. Cross, M. Tallman, M. Arcila, M. Roshal, G. Petsko, Bin Wu, S. Choe, Z. Konteatis, S. Biller, J. Chodera, C. Thompson, R. Levine, E. Stein (2018)
Acquired resistance to IDH inhibition through trans or cis dimer-interface mutationsNature, 559
-
M. Larrosa-Garcia, M. Baer (2017)
FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future DirectionsMolecular Cancer Therapeutics, 16
-
Lauren Lee, D. Hernandez, T. Rajkhowa, Samuel Smith, J. Raman, Bao Nguyen, D. Small, M. Levis (2017)
Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.Blood, 129 2
-
S. Castaigne, C. Pautas, C. Terré, E. Raffoux, D. Bordessoule, J. Bastie, O. Legrand, X. Thomas, P. Turlure, O. Reman, T. Revel, L. Gastaud, Noémie Gunzburg, N. Contentin, Estelle Henry, J. Marolleau, Ahmad Aljijakli, P. Rousselot, P. Fenaux, C. Preudhomme, S. Chevret, H. Dombret (2012)
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 studyThe Lancet, 379
-
R. Assi, F. Ravandi (2018)
FLT3 inhibitors in acute myeloid leukemia: Choosing the best when the optimal does not existAmerican Journal of Hematology, 93
-
Yiting Lim, L. Gondek, Li Li, Qiuju Wang, Hayley Ma, E. Chang, D. Huso, S. Foerster, L. Marchionni, Karen McGovern, D. Watkins, C. Peacock, M. Levis, B. Smith, Akil Merchant, D. Small, W. Matsui (2015)
Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemiaScience Translational Medicine, 7
-
A. Burnett, R. Hills, D. Milligan, L. Kjeldsen, J. Kell, N. Russell, J. Yin, A. Hunter, A. Goldstone, K. Wheatley (2011)
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 4
-
B. Ragon, C. Dinardo (2017)
Targeting IDH1 and IDH2 Mutations in Acute Myeloid LeukemiaCurrent Hematologic Malignancy Reports, 12
-
P. Bose, P. Vachhani, J. Cortes (2017)
Treatment of Relapsed/Refractory Acute Myeloid LeukemiaCurrent Treatment Options in Oncology, 18
-
M. Konopleva, A. Letai (2018)
BCL-2 inhibition in AML: an unexpected bonus?Blood, 132 10
-
A. Wei, S. Strickland, Jingzhou Hou, W. Fiedler, T. Lin, R. Walter, A. Enjeti, W. Hong, B. Chyla, R. Popovic, Kaffa Fakouhi, T. Xu, J. Hayslip, G. Roboz (2018)
Venetoclax with Low-Dose Cytarabine Induces Rapid, Deep, and Durable Responses in Previously Untreated Older Adults with AML Ineligible for Intensive ChemotherapyBlood
-
L. Budde, J. Song, Young Kim, S. Blanchard, J. Wagner, A. Stein, L. Weng, M. Real, Rochelle Hernandez, E. Marcucci, Jennifer Shepphird, Xiuli Wang, B. Wood, G. Marcucci, Christine Brown, S. Forman (2017)
Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123-Specific CAR T Cells: A First-in-Human Clinical TrialBlood, 130
-
E. Zimmerman, D. Turner, Jassada Buaboonnam, Shuiying Hu, S. Orwick, M. Roberts, L. Janke, A. Ramachandran, C. Stewart, H. Inaba, S. Baker (2013)
Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.Blood, 122 22
-
R. Stone, T. Fischer, R. Paquette, G. Schiller, C. Schiffer, G. Ehninger, J. Cortes, H. Kantarjian, D. DeAngelo, Alice Huntsman-Labed, C. Dutreix, A. Corral, F. Giles (2012)
Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemiaLeukemia, 26
-
Haobin Ye, Biniam Adane, Nabilah Khan, T. Sullivan, Mohammad Minhajuddin, M. Gasparetto, Brett Stevens, Shanshan Pei, M. Balys, J. Ashton, D. Klemm, Carolien Woolthuis, Alec Stranahan, Christopher Park, C. Jordan (2016)
Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche.Cell stem cell, 19 1
-
T. Tsao, Yue-xi Shi, S. Kornblau, Hongbo Lu, S. Konoplev, Ansu Antony, V. Ruvolo, Y. Qiu, Ninaxiang Zhang, K. Coombes, M. Andreeff, K. Kojima, M. Konopleva (2012)
Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cellsAnnals of Hematology, 91
-
K. Pratz (2018)
Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)Blood
-
J Lambert (2018)
10.3324/haematol.2018.188888Haematologica.
-
V. Clément, P. Sánchez, N. Tribolet, I. Radovanovic, A. Altaba (2007)
HEDGEHOG-GLI1 Signaling Regulates Human Glioma Growth, Cancer Stem Cell Self-Renewal, and TumorigenicityCurrent Biology, 17
-
(2013)
Differential regulation of myeloid leukemias by the bone marrow microenvironmentNat Med, 19
-
H. Dombret, J. Seymour, A. Butrym, A. Wierzbowska, D. Selleslag, J. Jang, Rajat Kumar, J. Cavenagh, A. Schuh, A. Candoni, C. Récher, I. Sandhu, T. Castillo, H. Al-Ali, G. Martinelli, J. Falantes, R. Noppeney, R. Stone, M. Minden, H. McIntyre, S. Songer, L. Lucy, C. Beach, H. Döhner (2015)
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.Blood, 126 3
-
N. Asada, Y. Katayama (2014)
Regulation of hematopoiesis in endosteal microenvironmentsInternational Journal of Hematology, 99
-
A. Saiki, S. Caenepeel, Dongyin Yu, J. Lofgren, T. Osgood, Rebecca Robertson, J. Canon, C. Su, Adrie Jones, Xiaoning Zhao, Chetan Deshpande, Marc Payton, J. Ledell, P. Hughes, J. Oliner (2014)
MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathwaysOncotarget, 5
-
DS Krause (2013)
10.1038/nm.3364Nat Med, 19
-
R. Stone, P. Manley, R. Larson, R. Capdeville (2018)
Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis.Blood advances, 2 4
-
C. Dinardo, K. Pratz, V. Pullarkat, B. Jonas, M. Arellano, P. Becker, O. Frankfurt, M. Konopleva, A. Wei, H. Kantarjian, T. Xu, W. Hong, B. Chyla, J. Potluri, D. Pollyea, A. Letai (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.Blood, 133 1
-
Lev Kats, Lev Kats, S. Vervoort, R. Cole, Amy Rogers, Gareth Gregory, Gareth Gregory, Gareth Gregory, E. Vidacs, Jason Li, Jason Li, R. Nagaraja, Katharine Yen, Ricky Johnstone, Ricky Johnstone (2017)
A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AMLLeukemia, 31
-
D. Pollyea, M. Tallman, S. Botton, C. Dinardo, H. Kantarjian, R. Collins, A. Stein, Qiang Xu, A. Tosolini, I. Gupta, S. Agresta, E. Stein (2017)
Enasidenib Monotherapy Is Effective and Well-Tolerated in Patients with Previously Untreated Mutant- IDH2 (m IDH2) Acute Myeloid Leukemia (AML)Blood, 130
-
M. Konopleva, D. Pollyea, J. Potluri, B. Chyla, L. Hogdal, T. Busman, E. Mckeegan, A. Salem, Ming Zhu, J. Ricker, W. Blum, C. Dinardo, T. Kadia, M. Dunbar, R. Kirby, N. Falotico, J. Leverson, R. Humerickhouse, M. Mabry, R. Stone, H. Kantarjian, A. Letai (2016)
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.Cancer discovery, 6 10
-
R. Assi, H. Kantarjian, F. Ravandi, N. Daver (2017)
Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitorsCurrent Opinion in Hematology, 25
-
C. Dinardo, E. Stein, S. Botton, G. Roboz, J. Altman, A. Mims, R. Swords, R. Collins, G. Mannis, D. Pollyea, W. Donnellan, A. Fathi, A. Pigneux, H. Erba, G. Prince, A. Stein, G. Uy, J. Foran, E. Traer, R. Stuart, M. Arellano, J. Slack, M. Sekeres, C. Willekens, S. Choe, Hongfang Wang, V. Zhang, K. Yen, S. Kapsalis, Hua Yang, D. Dai, Bin Fan, M. Goldwasser, Hua Liu, S. Agresta, Bin Wu, E. Attar, M. Tallman, R. Stone, H. Kantarjian (2018)
Durable Remissions with Ivosidenib in IDH1‐Mutated Relapsed or Refractory AMLThe New England Journal of Medicine, 378
-
E. Papaemmanuil, M. Gerstung, L. Bullinger, V. Gaidzik, P. Paschka, Nicola Roberts, N. Potter, M. Heuser, F. Thol, N. Bolli, G. Gundem, P. Loo, I. Martincorena, P. Ganly, L. Mudie, Stuart Mclaren, S. O'meara, K. Raine, David Jones, J. Teague, A. Butler, M. Greaves, A. Ganser, K. Döhner, R. Schlenk, H. Döhner, P. Campbell (2016)
Genomic Classification and Prognosis in Acute Myeloid Leukemia.The New England journal of medicine, 374 23
-
E. Weisberg, Christina Boulton, Louise Kelly, P. Manley, D. Fabbro, T. Meyer, D. Gilliland, D. Gilliland, James Griffin, James Griffin (2002)
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.Cancer cell, 1 5
-
S. Petersdorf, K. Kopecky, M. Slovak, C. Willman, T. Nevill, J. Brandwein, R. Larson, H. Erba, P. Stiff, R. Stuart, R. Walter, M. Tallman, L. Stenke, F. Appelbaum (2013)
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.Blood, 121 24
-
E. Stein, A. Shoben, U. Borate, M. Baer, W. Stock, P. Patel, T. Kovacsovics, W. Blum, J. Vergilio, N. Heerema, Leonard Rosenberg, S. Marcus, Mona Stefanos, Jordan Chervin, B. Druker, A. Burd, J. Byrd, R. Levine, A. Mims (2018)
Enasidenib Is Highly Active in Previously Untreated IDH2 Mutant AML: Early Results from the Beat AML Master TrialBlood
-
J. Randhawa, H. Kantarjian, G. Borthakur, P. Thompson, M. Konopleva, N. Daver, N. Pemmaraju, E. Jabbour, T. Kadia, Z. Estrov, A. Ramachandran, Jamil Paradela, M. Andreef, M. Levis, F. Ravandi, J. Cortes (2014)
Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 MutationsBlood, 124
-
G. Poeta, A. Venditti, M. Principe, L. Maurillo, F. Buccisano, A. Tamburini, M. Cox, A. Franchi, A. Bruno, C. Mazzone, P. Panetta, G. Suppo, M. Masi, S. Amadori (2003)
Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML).Blood, 101 6
-
A. Burnett, N. Russell, R. Hills, J. Kell, S. Freeman, L. Kjeldsen, A. Hunter, J. Yin, C. Craddock, I. Dufva, K. Wheatley, D. Milligan (2012)
Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 32
-
James Bogenberger, D. Delman, Nanna Hansen, R. Valdez, V. Fauble, R. Mesa, R. Tibes (2015)
Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignanciesLeukemia & Lymphoma, 56
-
C. Dinardo, K. Pratz, A. Letai, B. Jonas, A. Wei, M. Thirman, M. Arellano, M. Frattini, H. Kantarjian, R. Popovic, B. Chyla, T. Xu, M. Dunbar, S. Agarwal, R. Humerickhouse, M. Mabry, J. Potluri, M. Konopleva, D. Pollyea (2018)
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.The Lancet. Oncology, 19 2
-
E. Stein, G. Garcia-Manero, D. Rizzieri, R. Tibes, J. Berdeja, M. Savona, Mojca Jongen-Lavrenic, J. Altman, B. Thomson, S. Blakemore, S. Daigle, N. Waters, A. Suttle, A. Clawson, R. Pollock, A. Krivtsov, S. Armstrong, J. Dimartino, E. Hedrick, B. Löwenberg, M. Tallman (2018)
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.Blood, 131 24
-
E. Stein, C. Dinardo, A. Fathi, A. Mims, K. Pratz, M. Savona, A. Stein, R. Stone, E. Winer, C. Seet, H. Döhner, D. Pollyea, J. Mccloskey, O. Odenike, B. Löwenberg, G. Ossenkoppele, P. Patel, M. Roshal, F. Lersch, S. Nabhan, S. Choe, Hongfang Wang, L. Hua, Caroline Almon, Michael Cooper, M. Tallman (2018)
Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete RemissionsBlood
-
Grant Chappell, M. Geer, E. Gatza, T. Braun, Tracey Churay, J. Brisson, D. Bixby, B. Marini, Anthony Perissinotti, D. Frame, B. Parkin, P. Reddy, J. Magenau, S. Choi (2019)
Maintenance sorafenib in FLT3-ITD AML following allogeneic HCT favorably impacts relapse and overall survivalBone Marrow Transplantation
-
Anuhar Chaturvedi, M. Cruz, N. Jyotsana, Amar Sharma, Ramya Goparaju, A. Schwarzer, Kerstin Görlich, R. Schottmann, Eduard Struys, Erwin Jansen, Christian Rohde, Carsten Müller-Tidow, R. Geffers, G. Göhring, Arnold Ganser, Felicitas Thol, Michael Heuser (2016)
Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarateLeukemia, 30
-
F. Wang, J. Travins, B. Delabarre, V. Penard-Lacronique, S. Schalm, Erica Hansen, K. Straley, A. Kernytsky, Wei Liu, C. Gliser, Hua Yang, S. Gross, Erin Artin, V. Saada, E. Mylonas, C. Quivoron, Janeta Popovici-Muller, J. Saunders, F. Salituro, Shunqi Yan, Stuart Murray, Wentao Wei, Yi Gao, L. Dang, M. Dorsch, S. Agresta, D. Schenkein, S. Biller, Shinsan Su, S. Botton, K. Yen (2013)
Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular DifferentiationScience, 340
-
L Dang (2009)
10.1038/nature08617Nature, 462
-
R. Gale, T. Popa, Melissa Wright, N. Khan, S. Freeman, A. Burnett, N. Russell, R. Hills, D. Linch (2018)
No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials.Blood, 131 4
-
P. Ward, Jay Patel, David Wise, O. Abdel-Wahab, Bryson Bennett, H. Coller, J. Cross, V. Fantin, C. Hedvat, A. Perl, J. Rabinowitz, M. Carroll, Shinsan Su, K. Sharp, R. Levine, C. Thompson (2010)
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.Cancer cell, 17 3
-
J. Lancet, G. Uy, J. Cortes, L. Newell, T. Lin, E. Ritchie, R. Stuart, S. Strickland, D. Hogge, S. Solomon, R. Stone, D. Bixby, J. Kolitz, G. Schiller, M. Wieduwilt, D. Ryan, A. Hoering, Kamalika Banerjee, M. Chiarella, A. Louie, B. Medeiros (2018)
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid LeukemiaJournal of Clinical Oncology, 36
-
D. Irvine, M. Copland (2012)
Targeting hedgehog in hematologic malignancy.Blood, 119 10
-
E. Weisberg, M. Sattler, A. Ray, James Griffin (2010)
Drug resistance in mutant FLT3-positive AMLOncogene, 29
-
M. Levis, R. Pham, B. Smith, D. Small (2004)
In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects.Blood, 104 4
-
A. Perl, J. Cortes, S. Strickland, E. Ritchie, A. Neubauer, G. Martinelli, T. Naoe, A. Pigneux, P. Rousselot, C. Röllig, M. Baer, R. Larson, A. James, Caroline Chen, L. Shu, N. Hasabou, E. Bahceci (2017)
An open-label, randomized phase III study of gilteritinib versus salvage chemotherapy in relapsed or refractory FLT3 mutation-positive acute myeloid leukemia.Journal of Clinical Oncology, 35
-
R. Hills, S. Castaigne, F. Appelbaum, J. Delaunay, S. Petersdorf, M. Othus, E. Estey, H. Dombret, S. Chevret, N. Ifrah, J. Cahn, C. Récher, L. Chilton, A. Moorman, A. Burnett (2014)
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.The Lancet. Oncology, 15 9
-
R. Stone, S. Mandrekar, B. Sanford, K. Laumann, S. Geyer, C. Bloomfield, C. Thiede, T. Prior, K. Döhner, G. Marcucci, F. Lo‐Coco, R. Klisovic, A. Wei, J. Sierra, M. Sanz, J. Brandwein, T. Witte, D. Niederwieser, F. Appelbaum, B. Medeiros, M. Tallman, J. Krauter, R. Schlenk, A. Ganser, H. Serve, G. Ehninger, S. Amadori, R. Larson, H. Döhner (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 MutationThe New England Journal of Medicine, 377
-
N. Daver, Sreyashi Basu, G. Garcia-Manero, J. Cortes, F. Ravandi, E. Jabbour, Stephany Hendrickson, S. Pierce, J. Ning, M. Konopleva, M. Andreeff, S. Kornblau, N. Pemmaraju, C. Bueso-Ramos, J. Blando, Juliana Lopez, J. Allison, H. Kantarjian, P. Sharma (2016)
Phase IB/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML)Blood, 128
-
L. Dang, D. White, S. Gross, Bryson Bennett, M. Bittinger, E. Driggers, V. Fantin, H. Jang, Shengfang Jin, M. Keenan, K. Marks, R. Prins, P. Ward, K. Yen, L. Liau, J. Rabinowitz, L. Cantley, C. Thompson, M. Heiden, Shinsan Su (2010)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature, 465
-
E. Wang, R. Stone, M. Tallman, R. Walter, J. Eckardt, R. Collins (2016)
Crenolanib, a Type I FLT3 TKI, Can be Safely Combined with Cytarabine and Anthracycline Induction Chemotherapy and Results in High Response Rates in Patients with Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia (AML)Blood, 128
-
Xiaojia Niu, Jianyun Zhao, Jun Ma, C. Xie, Holly Edwards, Guan Wang, J. Caldwell, Shengyan Xiang, X. Zhang, R. Chu, Z. Wang, Hai Lin, J. Taub, J. Taub, Y. Ge (2016)
Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML CellsClinical Cancer Research, 22
-
J. Delaunay, C. Récher, A. Pigneux, F. Witz, N. Vey, O. Blanchet, P. Lefebvre, I. Luquet, Isabelle Guillerme, C. Volteau, E. Gyan, B. Lioure, E. Jourdan, D. Bouscary, R. Guièze, Edouard Randriamalala, M. Uribe, F. Dreyfus, C. Lacombe, M. Béné, J. Cahn, J. Harousseau, N. Ifrah (2011)
Addition of Gemtuzumab Ozogamycin to Chemotherapy Improves Event-Free Survival but Not Overall Survival of AML Patients with Intermediate Cytogenetics Not Eligible for Allogeneic Transplantation. Results of the GOELAMS AML 2006 IR StudyBlood, 118
-
I. Aldoss, Dongyun Yang, A. Aribi, H. Ali, Karamjeet Sandhu, M. Malki, M. Mei, A. Salhotra, S. Khaled, R. Nakamura, D. Snyder, M. O'donnell, A. Stein, S. Forman, G. Marcucci, V. Pullarkat (2018)
Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemiaHaematologica, 103
-
R. Larson, M. Boogaerts, E. Estey, C. Karanes, E. Stadtmauer, E. Sievers, P. Mineur, J. Bennett, M. Berger, C. Eten, M. Munteanu, M. Loken, J. Dongen, I. Bernstein, F. Appelbaum, for group (2002)
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)Leukemia, 16
-
S. Gross, R. Cairns, M. Minden, E. Driggers, M. Bittinger, H. Jang, M. Sasaki, Shengfang Jin, D. Schenkein, Shinsan Su, L. Dang, V. Fantin, T. Mak (2010)
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutationsThe Journal of Experimental Medicine, 207
-
(Konopleva M, Letai A. BCL-2 inhibition in AML—an unexpected bonus? Blood. 2018;132(10):1007–12. 10.1182/blood-2018-03-828269.)
Konopleva M, Letai A. BCL-2 inhibition in AML—an unexpected bonus? Blood. 2018;132(10):1007–12. 10.1182/blood-2018-03-828269.Konopleva M, Letai A. BCL-2 inhibition in AML—an unexpected bonus? Blood. 2018;132(10):1007–12. 10.1182/blood-2018-03-828269., Konopleva M, Letai A. BCL-2 inhibition in AML—an unexpected bonus? Blood. 2018;132(10):1007–12. 10.1182/blood-2018-03-828269.
-
G. Roboz, C. Dinardo, E. Stein, S. Botton, A. Mims, G. Prince, J. Altman, M. Arellano, W. Donnellan, H. Erba, G. Mannis, D. Pollyea, A. Stein, G. Uy, J. Watts, A. Fathi, H. Kantarjian, M. Tallman, S. Choe, D. Dai, Bin Fan, Hongfang Wang, V. Zhang, K. Yen, S. Kapsalis, D. Hickman, Hua Liu, S. Agresta, Bin Wu, E. Attar, R. Stone (2018)
Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion StudyBlood
-
(Pollyea DA, Tallman MS, Botton S, et al. Enasidenib monotherapy is effective and well- tolerated in patients with previously untreated mutant-IDH2 (mIDH2) acute myeloid leukemia (AML). HemaSphere. 2018;2:S1 (S1561).)
Pollyea DA, Tallman MS, Botton S, et al. Enasidenib monotherapy is effective and well- tolerated in patients with previously untreated mutant-IDH2 (mIDH2) acute myeloid leukemia (AML). HemaSphere. 2018;2:S1 (S1561).Pollyea DA, Tallman MS, Botton S, et al. Enasidenib monotherapy is effective and well- tolerated in patients with previously untreated mutant-IDH2 (mIDH2) acute myeloid leukemia (AML). HemaSphere. 2018;2:S1 (S1561)., Pollyea DA, Tallman MS, Botton S, et al. Enasidenib monotherapy is effective and well- tolerated in patients with previously untreated mutant-IDH2 (mIDH2) acute myeloid leukemia (AML). HemaSphere. 2018;2:S1 (S1561).
-
Usua Oyarbide, J. Topczewski, S. Corey (2018)
Peering through zebrafish to understand inherited bone marrow failure syndromesHaematologica, 104
-
C. Godwin, R. Gale, R. Walter, R. Walter (2017)
Gemtuzumab ozogamicin in acute myeloid leukemiaLeukemia, 31
-
M. Munchhof, Qifang Li, A. Shavnya, G. Borzillo, T. Boyden, Christopher Jones, Susan Lagreca, Luis Martinez-Alsina, N. Patel, Kathleen Pelletier, L. Reiter, M. Robbins, G. Tkalcevic (2012)
Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened.ACS medicinal chemistry letters, 3 2
-
M. Amatangelo, L. Quek, A. Shih, E. Stein, M. Roshal, M. David, B. Marteyn, N. Farnoud, S. Botton, O. Bernard, Bin Wu, K. Yen, M. Tallman, E. Papaemmanuil, V. Penard-Lacronique, A. Thakurta, P. Vyas, R. Levine (2017)
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.Blood, 130 6
-
G. Martinelli, V. Oehler, C. Papayannidis, R. Courtney, N. Shaik, Xiaoxi Zhang, A. O’Connell, K. Mclachlan, Xianxian Zheng, J. Radich, M. Baccarani, H. Kantarjian, W. Levin, J. Cortes, C. Jamieson (2015)
Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study.The Lancet. Haematology, 2 8
-
A. Goldberg, R. Collins, R. Stone, R. Walter, C. Karanes, C. Vigil, E. Wang, M. Tallman (2018)
Addition of Crenolanib to Induction Chemotherapy Overcomes the Poor Prognostic Impact of Co- Occurring Driver Mutations in Patients with Newly Diagnosed FLT3-Mutated AMLBlood
-
T. Kadia, J. Cortes, A. Ghorab, F. Ravandi, E. Jabbour, N. Daver, Y. Alvarado, M. Ohanian, M. Konopleva, H. Kantarjian (2018)
Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients.Journal of Clinical Oncology, 36
-
Cristina Mirantes, E. Passegué, E. Pietras (2014)
Pro-inflammatory cytokines: emerging players regulating HSC function in normal and diseased hematopoiesis.Experimental cell research, 329 2
-
K. Queiroz, K. Queiroz, K. Queiroz, R. Ruela-de-Sousa, R. Ruela-de-Sousa, G. Fuhler, Hella Aberson, C. Ferreira, M. Peppelenbosch, C. Spek (2010)
Hedgehog signaling maintains chemoresistance in myeloid leukemic cellsOncogene, 29
-
(FDA Briefing Document Oncologic Drugs Advisory Committee (ODAC) Meeting May 14, 2019 NDA 212166 Quizartinib Applicant: Daiichi-Sankyo, Inc. 2019.)
FDA Briefing Document Oncologic Drugs Advisory Committee (ODAC) Meeting May 14, 2019 NDA 212166 Quizartinib Applicant: Daiichi-Sankyo, Inc. 2019.FDA Briefing Document Oncologic Drugs Advisory Committee (ODAC) Meeting May 14, 2019 NDA 212166 Quizartinib Applicant: Daiichi-Sankyo, Inc. 2019., FDA Briefing Document Oncologic Drugs Advisory Committee (ODAC) Meeting May 14, 2019 NDA 212166 Quizartinib Applicant: Daiichi-Sankyo, Inc. 2019.
-
Erica Hansen, C. Quivoron, K. Straley, René Lemieux, Janeta Popovici-Muller, H. Sadrzadeh, Amir Fathi, C. Gliser, M. David, V. Saada, J. Micol, O. Bernard, M. Dorsch, Hua Yang, Michael Su, S. Agresta, S. Botton, V. Penard-Lacronique, K. Yen (2014)
AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex VivoBlood, 124
-
C. Röllig, H. Serve, A. Hüttmann, R. Noppeney, C. Müller-Tidow, U. Krug, C. Baldus, C. Brandts, V. Kunzmann, H. Einsele, A. Krämer, K. Schäfer‐Eckart, A. Neubauer, A. Burchert, Aristoteles Giagounidis, S. Krause, A. Mackensen, W. Aulitzky, R. Herbst, M. Hänel, A. Kiani, N. Frickhofen, J. Kullmer, U. Kaiser, H. Link, T. Geer, A. Reichle, C. Junghanss, R. Repp, F. Heits, H. Dürk, Jana Hase, Ina-Maria Klut, T. Illmer, M. Bornhäuser, M. Schaich, S. Parmentier, M. Görner, C. Thiede, M. Bonin, J. Schetelig, M. Kramer, W. Berdel, G. Ehninger (2015)
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.The Lancet. Oncology, 16 16
-
A. Shih, K. Shank, Cem Meydan, A. Intlekofer, P. Ward, C. Thompson, A. Melnick, J. Travins, K. Straley, C. Gliser, K. Yen, R. Levine (2014)
AG-221, a Small Molecule Mutant IDH2 Inhibitor, Remodels the Epigenetic State of IDH2-Mutant Cells and Induces Alterations in Self-Renewal/Differentiation in IDH2-Mutant AML Model in VivoBlood, 124
-
(Perl AE, et al. An open-label, randomized phase III study of gilteritinib versus salvage chemotherapy in relapsed or refractory FLT3 mutation-positive acute myeloid leukemia. J Clin Oncol. 2017;35(suppl; abstr #TPS7067). 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, 2017 June 2–6; Chicago.)
Perl AE, et al. An open-label, randomized phase III study of gilteritinib versus salvage chemotherapy in relapsed or refractory FLT3 mutation-positive acute myeloid leukemia. J Clin Oncol. 2017;35(suppl; abstr #TPS7067). 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, 2017 June 2–6; Chicago.Perl AE, et al. An open-label, randomized phase III study of gilteritinib versus salvage chemotherapy in relapsed or refractory FLT3 mutation-positive acute myeloid leukemia. J Clin Oncol. 2017;35(suppl; abstr #TPS7067). 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, 2017 June 2–6; Chicago., Perl AE, et al. An open-label, randomized phase III study of gilteritinib versus salvage chemotherapy in relapsed or refractory FLT3 mutation-positive acute myeloid leukemia. J Clin Oncol. 2017;35(suppl; abstr #TPS7067). 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, 2017 June 2–6; Chicago.
-
L. Quek, M. David, A. Kennedy, M. Metzner, M. Amatangelo, A. Shih, B. Stoilova, C. Quivoron, M. Heiblig, C. Willekens, V. Saada, S. Alsafadi, M. Vijayabaskar, A. Peniket, O. Bernard, S. Agresta, K. Yen, K. Macbeth, E. Stein, G. Vassiliou, R. Levine, S. Botton, A. Thakurta, V. Penard-Lacronique, P. Vyas (2018)
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenibNature Medicine, 24
-
JP Medema, H. Walczak, M. Hahne, V. Laurenzi (2010)
Cell DeathCell Death and Differentiation, 17
-
C. Dinardo, C. Rausch, C. Benton, T. Kadia, N. Jain, N. Pemmaraju, N. Daver, Wendy Covert, K. Marx, M. Mace, E. Jabbour, J. Cortes, G. Garcia-Manero, F. Ravandi, K. Bhalla, H. Kantarjian, M. Konopleva (2018)
Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignanciesAmerican Journal of Hematology, 93
-
(2002)
in first relapse using Mylotarg ( gemtuzumab ozogam - icin ) -
B. Chyla, N. Daver, K. Doyle, E. Mckeegan, Xin Huang, V. Ruvolo, Zixing Wang, Ken Chen, A. Souers, J. Leverson, J. Potluri, E. Boghaert, A. Bhathena, M. Konopleva, R. Popovic (2018)
Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemiaAmerican Journal of Hematology, 93
-
Selin Kucukyurt, A. Eşkazan (2019)
New drugs approved for acute myeloid leukaemia in 2018British Journal of Clinical Pharmacology, 85
-
S. Knapper, K. Mills, A. Gilkes, S. Austin, V. Walsh, A. Burnett (2006)
The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases.Blood, 108 10
-
Peter Bross, J. Beitz, Gang Chen, X. Chen, E. Duffy, L. Kieffer, Sandip Roy, R. Sridhara, Atiqur Rahman, G. Williams, R. Pazdur (2001)
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.Clinical cancer research : an official journal of the American Association for Cancer Research, 7 6
-
R. Majeti (2011)
Monoclonal antibody therapy directed against human acute myeloid leukemia stem cellsOncogene, 30
-
Guillaume Olombel, E. Guérin, J. Guy, J. Perrot, F. Dumézy, A. Labarthe, J. Bastie, O. Legrand, E. Raffoux, A. Plesa, O. Wagner-Ballon, E. Cornet, V. Salaun, C. Preudhomme, X. Thomas, C. Pautas, S. Chantepie, P. Turlure, S. Castaigne, H. Dombret, J. Feuillard (2016)
The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.Blood, 127 17
-
J. Cortes, A. Perl, H. Döhner, H. Kantarjian, G. Martinelli, T. Kovacsovics, P. Rousselot, B. Steffen, H. Dombret, E. Estey, S. Strickland, J. Altman, C. Baldus, A. Burnett, A. Krämer, N. Russell, N. Shah, Catherine Smith, E. Wang, N. Ifrah, G. Gammon, D. Trone, D. Lazzaretto, M. Levis (2018)
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.The Lancet. Oncology, 19 7
-
J. Cortes, B. Smith, E. Wang, Akil Merchant, V. Oehler, M. Arellano, D. DeAngelo, D. Pollyea, M. Sekeres, T. Robak, W. Ma, M. Zeremski, N. Shaik, A. Laird, A. O’Connell, G. Chan, M. Schroeder (2018)
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study resultsAmerican Journal of Hematology, 93
-
Fang Liu, Yuanzhen Cao, K. Pinz, Yu Ma, M. Wada, Kevin Chen, Gina Ma, Jiaqi Shen, Charlotte Tse, Yi Su, Yisong Xiong, Guang-cui He, Yecheng Li, Yupo Ma (2018)
First-in-Human CLL1-CD33 Compound CAR T Cell Therapy Induces Complete Remission in Patients with Refractory Acute Myeloid Leukemia: Update on Phase 1 Clinical TrialBlood
-
T. Teh, T. Teh, Nhu-Y.N. Nguyen, D. Moujalled, D. Segal, D. Segal, Giovanna Pomilio, Sewa Rijal, A. Jabbour, K. Cummins, Kurt Lackovic, Kurt Lackovic, P. Blombery, Ella Thompson, P. Ekert, G. Lessene, G. Lessene, Stefan Glaser, Stefan Glaser, David Huang, D. Huang, Andrew Roberts, M. Guthridge, Andrew Wei, Andrew Wei (2018)
Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1Leukemia, 32
-
Christopher Ndugwa (2013)
Sickle cell anaemia and malaria in UgandaJournal of Blood Disorders and Transfusion
-
Y. Minami, H. Minami, T. Miyamoto, G. Yoshimoto, Y. Kobayashi, W. Munakata, Y. Onishi, Masahiro Kobayashi, M. Ikuta, G. Chan, A. Woolfson, Chiho Ono, M. Shaik, Yosuke Fujii, Xianxian Zheng, T. Naoe (2017)
Phase I study of glasdegib (PF‐04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignanciesCancer Science, 108
-
N. Daver, G. Garcia-Manero, Sreyashi Basu, J. Cortes, F. Ravandi, T. Kadia, M. Konopleva, E. Jabbour, C. Dinardo, R. Assi, S. Pierce, Y. Alvarado, Z. Estrov, N. Pemmaraju, Koichi Takahashi, J. Ning, G. Gonzalez, S. Kornblau, M. Alfayez, J. Matthews, W. Flores, J. Blando, J. Allison, P. Sharma, H. Kantarjian (2018)
Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 StudyBlood
-
M. Savona, D. Pollyea, W. Stock, V. Oehler, Mark Schroeder, J. Lancet, J. Mccloskey, H. Kantarjian, W. Ma, M. Shaik, A. Laird, M. Zeremski, A. O’Connell, G. Chan, Jorge Cortes (2018)
Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDSClinical Cancer Research, 24
-
A. Burnett, J. Cavenagh, N. Russell, R. Hills, J. Kell, G. Jones, O. Nielsen, A. Khwaja, Ian Thomas, R. Clark (2016)
Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 TrialHaematologica, 101
-
J. Cortes, F. Heidel, M. Heuser, W. Fiedler, B. Smith, T. Robak, P. Fernandez, W. Ma, N. Shaik, M. Zeremski, A. O’Connell, G. Chan (2016)
A Phase 2 Randomized Study of Low Dose Ara-C with or without Glasdegib (PF-04449913) in Untreated Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeBlood, 128
-
Chen Zhao, Alan Chen, C. Jamieson, M. Fereshteh, Annelie Abrahamsson, Jordan Blum, H. Kwon, Jynho Kim, J. Chute, D. Rizzieri, M. Munchhof, T. Vanarsdale, P. Beachy, T. Reya (2009)
Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemiaNature, 458
-
Matthew Waitkus, B. Diplas, Hai Yan (2018)
Biological Role and Therapeutic Potential of IDH Mutations in Cancer.Cancer cell, 34 2
-
S. Amadori, S. Suciu, D. Selleslag, F. Aversa, G. Gaidano, M. Musso, L. Annino, A. Venditti, M. Voso, C. Mazzone, D. Magro, P. Fabritiis, P. Muus, G. Alimena, M. Mancini, A. Hagemeijer, F. Paoloni, M. Vignetti, P. Fazi, L. Meert, S. Ramadan, R. Willemze, T. Witte, F. Baron (2016)
Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 9
- Publisher
- Springer Journals
- Copyright
- Copyright © The Author(s) 2020
- ISSN
- 2366-1070
- eISSN
- 2366-1089
- DOI
- 10.1007/s40487-019-00108-x
- Publisher site
- See Article on Publisher Site
Abstract
Acute myeloid leukemia (AML) is a complex disease characterized by genetic and clinical heterogeneity and high mortality. After 40 years during which the standard of care for patients evolved very little, the therapeutic landscape has recently seen rapid changes, with the approval of eight new drugs by the Food and Drug Administration (FDA) within the last 2 years, providing new opportunities, as well as new challenges, for treating clinicians. These therapies include FLT3 inhibitors midostaurin and gilteritinib, CPX-351 (liposomal cytarabine and daunorubicin), gemtuzumab ozogamicin (GO, anti-CD33 monoclonal antibody conjugated with calicheamicin), IDH1/IDH2 inhibitors ivosidenib and enasidenib, Hedgehog inhibitor glasdegib, and BCL-2 inhibitor venetoclax. In this review, we summarize currently available data on these new drugs and discuss the rapidly evolving therapeutic armamentarium for AML, focusing on targeted therapies.
Journal
Oncology and Therapy – Springer Journals
Published: Jun 24, 2020